Table 1 Clinical characteristics of the study population before and after aerosolised A1AT augmentation
CriteriaBefore aerosolised A1AT augmentationAfter aerosolised A1AT augmentation
Age (years)52 (8)
M/F60/40
FEV1 (% predicted)60.9 (12.4)60.8 (10.5)
FEV1/FVC (%)53.7 (15.3)52.0 (15.6)
Neutrophil counts (% of total cells)27.0 (20.5)31.3 (22.7)
NE activity (nM/ELF)297.0 (325.4)0.00*

  • Data are presented as median (SD).

  • A1AT, α1-antitrypsin; ELF, epithelial lining fluid; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; NE, neutrophil elastase.

  • *p<0.05 pre-treatment vs post-treatment.